Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Vanessa, Rai"'
Autor:
Matthew S. Davids, Svitlana Tyekucheva, Vanessa Rai, David C. Fisher, James A. Lederer, Emily M. Thrash, Stacey M. Fernandes, Stephen P. Martindale, Alec Griffith, Jennifer R. Brown, Oreofe O. Odejide, Brandon Lee, Timothy Z. Lehmberg, Zixu Wang, Jon E. Arnason, Deepti Gadi, John-Hanson Machado, Philippe Armand, Alexander R. Vartanov
Publikováno v:
Leukemia. 36:723-732
Several PI3Kδ inhibitors are approved for the therapy of B cell malignancies, but their clinical use has been limited by unpredictable autoimmune toxicity. We have recently reported promising efficacy results in treating chronic lymphocytic leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb1b7abf44624c518d572011b6d869f8
https://doi.org/10.1038/s41375-021-01441-9
https://doi.org/10.1038/s41375-021-01441-9
Autor:
Deepti Gadi, Alec Griffith, Zixu Wang, Svitlana Tyekucheva, Vanessa Rai, Stacey M. Fernandes, John‐Hanson Machado, Veerendra Munugalavadla, James Lederer, Jennifer R. Brown
Publikováno v:
Br J Haematol
Phosphatidylinositol 3 kinase (PI3K) inhibitors such as idelalisib have been associated with potentially severe autoimmune toxicity. In the present study, we demonstrate that relapsed refractory patients with chronic lymphocytic leukaemia treated wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d76526f20201d862559fad0e3eac0763
https://europepmc.org/articles/PMC9263710/
https://europepmc.org/articles/PMC9263710/
Autor:
Deepti, Gadi, Alec, Griffith, Svitlana, Tyekucheva, Zixu, Wang, Vanessa, Rai, Alexander, Vartanov, Emily, Thrash, Stacey M, Fernandes, Timothy Z, Lehmberg, Brandon, Lee, Stephen P, Martindale, John-Hanson, Machado, Oreofe, Odejide, Philippe, Armand, David C, Fisher, Jon, Arnason, Matthew S, Davids, James A, Lederer, Jennifer R, Brown
Publikováno v:
Leukemia. 36(3)
Several PI3Kδ inhibitors are approved for the therapy of B cell malignancies, but their clinical use has been limited by unpredictable autoimmune toxicity. We have recently reported promising efficacy results in treating chronic lymphocytic leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bd81a1c45e4a525cd7d71314a730b05c
https://pubmed.ncbi.nlm.nih.gov/34743191
https://pubmed.ncbi.nlm.nih.gov/34743191
Autor:
Winnie I Nguy, Kevin Ebata, Barb J. Brandhuber, Stephen M. Rothenberg, Jennifer R. Brown, Stacey M. Fernandes, Aishath S Naeem, Eliana B. Gomez, Svitlana Tyekucheva, Vanessa Rai
Publikováno v:
Blood. 134:478-478
Clinical success with the targeted Bruton Tyrosine Kinase (BTK) inhibitors ibrutinib and acalabrutinib has greatly improved the outcome of patients with relapsed chronic lymphocytic leukemia (CLL). However toxic side effects and acquired resistance d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6555187c705733fa86c2bf33b42ced8
https://doi.org/10.1182/blood-2019-124362
https://doi.org/10.1182/blood-2019-124362
Autor:
Deepti Gadi, Barbara Sherry, Stacey M. Fernandes, Yang Pan, Jennifer R. Brown, Alexander R. Vartanov, Svitlana Tyekucheva, Vanessa Rai, James A. Lederer, Alec Griffith, Pui Yan Chiu, Siddha Kasar
Publikováno v:
Blood. 134:1745-1745
Idelalisib and duvelisib are FDA approved oral inhibitors of PI3K delta and PI3K delta/gamma, respectively. Previously, we reported a decrease in regulatory T cells (Tregs) associated with autoimmune hepatotoxicity in untreated CLL patients receiving
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24598da44d195b90d38f47e6c6d1b789
https://doi.org/10.1182/blood-2019-122961
https://doi.org/10.1182/blood-2019-122961